Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Status unconfirmed · Phase 2
Conditions studied: Prostate Cancer
In brief
Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.
Key facts
- Study ID
- NCT01296243
- Run by
- Genta Incorporated
- People needed
- 57
- Starts
- 2011-02-01
- Expected to finish
- 2015-02-01
- Last updated by the study team
- 2012-07-24
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- University of Michigan Health System — Ann Arbor, Michigan, United States (enrolling)
- The Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.